ES2443194T3 - Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales - Google Patents

Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales Download PDF

Info

Publication number
ES2443194T3
ES2443194T3 ES05773576.3T ES05773576T ES2443194T3 ES 2443194 T3 ES2443194 T3 ES 2443194T3 ES 05773576 T ES05773576 T ES 05773576T ES 2443194 T3 ES2443194 T3 ES 2443194T3
Authority
ES
Spain
Prior art keywords
cis
retinyl
retinal
acid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05773576.3T
Other languages
English (en)
Spanish (es)
Inventor
Krzysztof Palczewski
Matthew Batten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Application granted granted Critical
Publication of ES2443194T3 publication Critical patent/ES2443194T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES05773576.3T 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales Expired - Lifetime ES2443194T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US580889 1995-12-29
US58088904P 2004-06-18 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (1)

Publication Number Publication Date
ES2443194T3 true ES2443194T3 (es) 2014-02-18

Family

ID=35782277

Family Applications (4)

Application Number Title Priority Date Filing Date
ES05773576.3T Expired - Lifetime ES2443194T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
ES11163940T Expired - Lifetime ES2752924T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
ES11163943.1T Expired - Lifetime ES2644981T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
ES11163947.2T Expired - Lifetime ES2644984T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES11163940T Expired - Lifetime ES2752924T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
ES11163943.1T Expired - Lifetime ES2644981T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
ES11163947.2T Expired - Lifetime ES2644984T3 (es) 2004-06-18 2005-06-20 Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales

Country Status (26)

Country Link
US (8) US7951841B2 (enExample)
EP (5) EP2397131B1 (enExample)
JP (2) JP5166026B2 (enExample)
KR (4) KR101337321B1 (enExample)
CN (2) CN102976937B (enExample)
AU (1) AU2005257997B2 (enExample)
BR (1) BRPI0511396B1 (enExample)
CA (2) CA2931917A1 (enExample)
CY (2) CY1114873T1 (enExample)
DK (2) DK1765322T3 (enExample)
ES (4) ES2443194T3 (enExample)
HR (1) HRP20140116T1 (enExample)
HU (1) HUE036596T2 (enExample)
IL (4) IL180078A (enExample)
IN (1) IN2012DN09335A (enExample)
LT (1) LT2397133T (enExample)
MX (2) MXPA06014750A (enExample)
NO (1) NO339969B1 (enExample)
NZ (2) NZ552080A (enExample)
PL (2) PL2397133T3 (enExample)
PT (2) PT1765322E (enExample)
RS (1) RS53178B (enExample)
RU (2) RU2408578C2 (enExample)
SI (2) SI2397133T1 (enExample)
WO (1) WO2006002097A2 (enExample)
ZA (1) ZA200700368B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520393A (ja) 2003-03-14 2006-09-07 ユニバーシティ オブ ワシントン レチノイド補充物およびオプシンアゴニスト、ならびにそれらの使用法
AU2005257997B2 (en) * 2004-06-18 2012-04-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2005262558B8 (en) 2004-06-23 2008-04-10 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006063128A2 (en) * 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CA2657238A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
US8338394B2 (en) * 2006-10-12 2012-12-25 Case Western Reserve University Methods for treating metabolic diseases
JP5371953B2 (ja) 2007-04-20 2013-12-18 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療するスチレニル誘導体化合物
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US8324270B2 (en) * 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
EP2296682B8 (en) * 2008-04-29 2018-07-04 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CA2774168C (en) * 2009-09-15 2021-02-23 Ronald Erwin Boch Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
SG184971A1 (en) * 2010-04-19 2012-11-29 Quadra Logic Tech Inc Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
CN106106368A (zh) * 2010-11-05 2016-11-16 斯坦福大学托管董事会 光控cns功能障碍
US10226536B2 (en) * 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
MX370928B (es) * 2012-03-01 2020-01-08 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
CA2875798A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
WO2013188727A2 (en) * 2012-06-15 2013-12-19 The Children's Hospital Of Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2017258776B2 (en) * 2016-04-28 2023-07-13 Spark Therapeutics, Inc. Relative potency assay for viral vector encoding isomerohydrolases
US20250161254A1 (en) * 2022-02-04 2025-05-22 New York University Use of retinoids for treatment of atrial fibrillation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) * 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) * 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
EP0818988A2 (en) * 1995-04-03 1998-01-21 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Skin care compositions containing retinoids and liposomes
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
ATE375141T1 (de) 2000-03-10 2007-10-15 Insite Vision Inc Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
WO2002055540A1 (en) 2001-01-11 2002-07-18 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
CA2435410A1 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
AU2003210597A1 (en) * 2002-01-18 2003-07-30 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CA2480047A1 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
JP2006520393A (ja) 2003-03-14 2006-09-07 ユニバーシティ オブ ワシントン レチノイド補充物およびオプシンアゴニスト、ならびにそれらの使用法
US20080176952A1 (en) 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
AU2005257997B2 (en) 2004-06-18 2012-04-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2005262558B8 (en) 2004-06-23 2008-04-10 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
EP2687208A1 (en) 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
US8324270B2 (en) 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
EP2397131B1 (en) 2019-09-11
CA2931917A1 (en) 2006-01-05
KR20140140616A (ko) 2014-12-09
US9174936B2 (en) 2015-11-03
RU2408578C2 (ru) 2011-01-10
ES2752924T3 (es) 2020-04-06
KR20070026817A (ko) 2007-03-08
US20130072556A1 (en) 2013-03-21
US20130072560A1 (en) 2013-03-21
US20080221208A1 (en) 2008-09-11
NO339969B1 (no) 2017-02-20
LT2397133T (lt) 2018-01-10
ZA200700368B (en) 2008-10-29
EP1765322B1 (en) 2013-11-06
NZ587006A (en) 2011-12-22
IL180078A (en) 2014-01-30
US9169204B2 (en) 2015-10-27
US9388130B2 (en) 2016-07-12
BRPI0511396B1 (pt) 2021-07-27
MX359668B (es) 2018-10-05
WO2006002097A2 (en) 2006-01-05
EP2397130B1 (en) 2019-04-03
WO2006002097A3 (en) 2006-05-04
PT1765322E (pt) 2014-02-05
JP5166026B2 (ja) 2013-03-21
JP2012229234A (ja) 2012-11-22
PL2397133T3 (pl) 2018-01-31
US20170014368A1 (en) 2017-01-19
PL1765322T3 (pl) 2014-04-30
IL180078A0 (en) 2007-05-15
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
SI1765322T1 (sl) 2014-03-31
EP2397133A3 (en) 2012-07-11
CN102976937B (zh) 2016-12-21
KR20130079669A (ko) 2013-07-10
BRPI0511396A (pt) 2007-12-04
RU2554003C2 (ru) 2015-06-20
US20190167626A1 (en) 2019-06-06
US9162978B2 (en) 2015-10-20
EP2397131A3 (en) 2012-10-31
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
US20130072559A1 (en) 2013-03-21
EP2397130A3 (en) 2012-10-31
EP1765322A4 (en) 2008-09-17
CA2571049A1 (en) 2006-01-05
NZ552080A (en) 2011-03-31
HUE036596T2 (hu) 2018-07-30
CN102976937A (zh) 2013-03-20
EP2397132A2 (en) 2011-12-21
EP2397133B1 (en) 2017-07-26
EP2397132A3 (en) 2012-07-11
EP2397133A2 (en) 2011-12-21
IL230241A (en) 2015-06-30
US20130079403A1 (en) 2013-03-28
MXPA06014750A (es) 2007-03-21
EP2397131A2 (en) 2011-12-21
RS53178B (sr) 2014-06-30
US7951841B2 (en) 2011-05-31
CY1114873T1 (el) 2016-12-14
ES2644981T3 (es) 2017-12-01
ES2644984T3 (es) 2017-12-01
KR101323122B1 (ko) 2013-10-30
EP2397130A2 (en) 2011-12-21
US20110288170A1 (en) 2011-11-24
EP1765322A2 (en) 2007-03-28
HK1098696A1 (en) 2007-07-27
CY1119480T1 (el) 2018-03-07
JP5596749B2 (ja) 2014-09-24
JP2008503496A (ja) 2008-02-07
DK1765322T3 (da) 2014-02-10
CA2571049C (en) 2016-08-09
RU2010138410A (ru) 2012-03-27
SI2397133T1 (sl) 2017-12-29
US10117845B2 (en) 2018-11-06
AU2005257997A1 (en) 2006-01-05
AU2005257997B2 (en) 2012-04-05
KR101490145B1 (ko) 2015-02-05
CN1988898A (zh) 2007-06-27
RU2007101735A (ru) 2008-07-27
IL222347A (en) 2017-08-31
IL230242A (en) 2015-10-29
US9403765B2 (en) 2016-08-02
NO20070330L (no) 2007-03-15
CN1988898B (zh) 2012-12-26
IN2012DN09335A (enExample) 2015-08-21
PT2397133T (pt) 2017-10-23
HRP20140116T1 (hr) 2014-03-28

Similar Documents

Publication Publication Date Title
ES2443194T3 (es) Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
AU2015207903B2 (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165300B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1098696B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165299B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165299A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165696A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165300A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1165298A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders